Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders
Alzheimer's & Dementia · 2023-05 · 19 (5) · 1775-1784
DOI: 10.1002/alz.12809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 14.10.2022. Verfasst von Johanna Nilsson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases, Frontotemporal Lobar Degeneration. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Introduction
Synaptic degeneration is a key part of the pathophysiology of neurodegenerative diseases, and biomarkers reflecting the pathological alterations are greatly needed.
Method
Seventeen synaptic proteins were quantified in a pathology‐confirmed cerebrospinal fluid cohort of patients with Alzheimer's disease (AD; n = 63), frontotemporal lobar degeneration (FTLD; n = 53), and Lewy body spectrum of disorders (LBD; n = 21), as well as healthy controls (HC; n = 48).
Results
Comparisons revealed four distinct patterns: markers decreased across all neurodegenerative conditions compared to HC (the neuronal pentraxins), markers increased across all neurodegenerative conditions (14‐3‐3 zeta/delta), markers selectively increased in AD compared to other neurodegenerative conditions (neurogranin and beta‐synuclein), and markers selectively decreased in LBD and FTLD compared to HC and AD (AP2B1 and syntaxin‐1B).
Discussion
Several of the synaptic proteins may serve as biomarkers for synaptic dysfunction in AD, LBD, and FTLD. Additionally, differential patterns of synaptic protein alterations seem to be present across neurodegenerative diseases. Highlights A panel of synaptic proteins were quantified in the cerebrospinal fluid using mass spectrometry. We compared Alzheimer's disease, frontotemporal degeneration, and Lewy body spectrum of disorders. Pathology was confirmed by autopsy or familial mutations. We discovered synaptic biomarkers for synaptic degeneration and cognitive decline. We found differential patterns of synaptic proteins across neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- UK Dementia Research Institute at UCL, London, UK.
- Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
Zitieren
APA
Nilsson, J., Cousins, K. A. Q., Gobom, J., Portelius, E., Chen-Plotkin, A., Shaw, L. M., Grossman, M., Irwin, D. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Brinkmalm, A. (2023). Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. Alzheimer's & Dementia, 19(5), 1775-1784. https://doi.org/10.1002/alz.12809
Vancouver
Nilsson J, Cousins KAQ, Gobom J, Portelius E, Chen-Plotkin A, Shaw LM, et al. Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. Alzheimer's & Dementia. 2023;19(5):1775-1784. doi:10.1002/alz.12809
BibTeX
@article{Nilsson2023,
author = {Nilsson, Johanna and Cousins, Katheryn A Q and Gobom, Johan and Portelius, Erik and Chen-Plotkin, Alice and Shaw, Leslie M and Grossman, Murray and Irwin, David J and Trojanowski, John Q and Zetterberg, Henrik and Blennow, Kaj and Brinkmalm, Ann},
title = {Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {5},
pages = {1775--1784},
doi = {10.1002/alz.12809}
}
EUVIMED